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Introduction
Several aspects of secondary progressive multiple 
sclerosis (SPMS) are still poorly understood. 
Despite high inter-individual variability, natural 
history studies investigating large cohorts of MS 
patients reveal that SPMS begins after a median dis-
ease duration of about 19 years1,2 and that disease 
progression is continuous, after certain disability 
milestones are reached.3
Reliable prediction of onset and speed of progression 
could facilitate patient selection for treatment trials; 
however, the only reported predictors of slow disability 
accumulation in SPMS are the occurrence of relapses 
and a longer time to onset of progression.2,4 Although 
distinctive imaging features are not well established, 
studies show a higher T2-lesion load in SPMS than in 
primary progressive MS (PPMS)5 and suggest distinc-
tive T1 hypointense evolution and atrophy patterns in 
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Abstract
Objectives: To explore long-term effects of treatment and prognostic relevance of variables assessed at 
baseline and during the European secondary progressive multiple sclerosis (SPMS) trial of interferon beta 
1b (IFNB-1b).
Methods: We assessed 362 patients (60% female; median age 41 years; Expanded Disability Status Scale 
(EDSS): 5.5; 51% randomized to IFNB-1b) for their EDSS and treatment history after 10 years. Non-
parametric analysis of covariance (ANCOVA) and multivariate linear regression models were applied.
Results: Median EDSS was 6.0 at the end of the randomized controlled trial (RCT), in the IFNB-1b 
and placebo groups, and 7.0 in long-term follow-up patients (those receiving IFNB-1b in the RCT were 
6.5 and those receiving placebo in the RCT were 7.0; p = 0.086). 24 patients (6.6%) were deceased. 
The EDSS at baseline and the EDSS change during the RCT were the most important predictors of the 
EDSS 10 years later (partial R2: 0.47). The ability to predict changes in EDSS 10 years after the RCT 
was limited (R2: 0.12). Magnetic resonance imaging (MRI) measures remained in the predictive 
models, but explained < 5% of the variability.
Conclusions: The results from this analysis did not provide convincing evidence to support a favorable 
long-term outcome in those patients allocated IFNB-1b during the RCT, in our SPMS cohort. The pro-
gressive stage of the disease remains largely unpredictable by clinical and conventional MRI measures, 
so better prognostic markers are needed.
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SPMS, in comparison to relapsing–remitting MS 
(RRMS) and PPMS.6 Furthermore, a small longitudi-
nal study found that grey matter atrophy and T2-lesion 
load were the most relevant predictors for conversion 
to SPMS, in a 13-year follow-up.7
Treatment options in SPMS are limited. A positive 
effect of interferon-beta 1b (IFNB-1b) was found in 
the European SPMS study (EU-SPMS),8 but this was 
not replicated in the North American SPMS trial, pos-
sibly due to differences in the selection of patients.9,10 
It was not seen for IFNB-1a.11,12
Despite this, the long-term effects of these treatments 
in SPMS patients are not known. Long-term follow-
up (LTFU) studies of randomized controlled trials 
(RCTs) in RRMS have often indicated beneficial 
outcomes in patients initially randomized to the 
active drug.13–16 Nevertheless, these studies are fre-
quently criticized for methodological constraints, 
such as selection bias, i.e. the attrition of deteriorating 
patients, which potentially flaw the generalizability of 
their results17,18; however, because patients recruited 
for treatment trials are well characterized and pro-
spectively followed during the RCT, clinically and by 
magnetic resonance imaging (MRI), they constitute a 
valuable source to elucidate prognostic factors and 
may still allow for limited estimations of long-term 
treatment effects. In a 10-year LTFU, we explored 
these two objectives in 362 patients originally included 
into the EU-SPMS trial.8
Methods
EU-SPMS trial and open-label extension
The EU-SPMS trial was a multicenter, double-blind 
trial comparing IFNB-1b to placebo, conducted on 
718 patients between 1995 and 1998.8 The patients 
were randomly assigned to receive either IFNB-1b (8 
MIU) every other day (n = 360), or placebo (n = 358). 
After completion of the 3-year RCT, all patients were 
offered the chance to receive IFNB-1 in an open-label 
(OL) extension that lasted for an additional 18 months. 
Thereafter, treatment decisions were not protocol-
defined, but at the discretion of the treating physicians 
and patients.
Long-term follow-up: Patients and data collection
At the end of OL extension, all 35 EU-SPMS centers 
were asked to provide long-term observational data on 
their patients. After obtaining ethical approval and writ-
ten informed consent, 23 centers took part in the LTFU 
and provided data by a standardized documentation 
form, every 6 or 12 months. Demographic data, the 
patients’ Expanded Disability Status Scale (EDSS) 
score, clinical status (i.e. stable or in relapse), and both 
the change in treatment and occurrence of relapses were 
captured. The EDSS values obtained during a relapse 
were excluded. EDSS values from 362 patients were 
documented between months 112 and 152 (a time-span 
referred to as Year 10). Of these 362 patients, 186 
(51.4%) were originally randomized to IFNB-1b and 
176 (48.6%) to placebo; while 24 (6.6%) were deceased 
(Figure 1).
The baseline characteristics of the LTFU and non-
LTFU patients are provided in Table 1. LTFU partici-
pants had a median EDSS of 5.5 (interquartile range 
(IQR): 4.0–6.0) divided into the following EDSS cat-
egories: EDSS 3.0–3.5 (n = 66), EDSS 4.0–5.5 (n = 
139) and EDSS 6.0–6.5 (n = 157).
We collected and analyzed the MRI measures 
centrally, according to standardized protocols.19 
Notably, the EDSS is not a linear measure and the 
time during which scores increase is not equally dis-
tributed across the scale.20 Therefore, as in the 
EU-SPMS trial, the EDSS changes from EDSS 6.0 
to 6.5, and from EDSS 6.5 to 7.0, were considered as 
equivalent to a 1.0-point change (see the supplemen-
tary Table S1).
Statistics
Continuous variables are presented as median with 
interquartile range (IQR); and categorical variables as 
Figure 1. Patient disposition. The number of patients 
with a LTFU as part of the EU-SPMS cohort, their original 
treatment allocation and the number of deaths within the 
subgroups.
EU-SPMS: European SPMS study; LTFU: long-term follow-up; 
MS: multiple sclerosis; RCT: randomized controlled trial;  
SPMS: secondary progressive MS.
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numbers and proportions. In order to explore bias in 
patient ascertainment, the baseline and on-trial char-
acteristics were compared between the LTFU versus 
the non-LTFU centers, and participating versus non-
participating patients (both overall and within the 
LTFU centers), by Fisher’s exact test or Wilcoxon 
rank sum test.
In an intention-to-treat analysis, we compared the 
EDSS at Year 3 and Year 10 and the change in EDSS 
from baseline to Year 3 and Year 10, between the 
IFNB-1b and placebo groups, using the Wilcoxon test 
at baseline and a nonparametric analysis of covariance 
(ANCOVA) with covariate adjustment for baseline 
EDSS, at Year 3 and Year 10, as in the EU-SPMS trial.
We determined the prognostic factors for long-term 
outcome using multivariate linear regression mod-
els, in which the baseline (Table 1), RCT measures 
(Table 2) and the treatment allocation during the 
EU-SPMS were used as predictors of EDSS at Year 
10 and the change in EDSS from the end of the RCT 
to Year 10. We employed a stepwise elimination 
procedure, with p < 0.5 to enter and p < 0.05 to stay 
in the model, to determine the weights of the most 
informative set of predictors in the final model. 
Multivariate models included 94.2% of the LTFU 
patients, due to the fact that in 21 patients the change 
in T2 lesion volume (T2 burden of disease (BOD)) 
was not available. The EDSS change in the 2 years 
prior to study inclusion was tested only in univari-
ate models, as it was only assessed in a subgroup of 
patients (n = 275).
Deaths were considered as EDSS 10. The Kaplan-
Meier curves of IFNB-1b and placebo patients were 
compared by a log-rank test. P-values lower than 0.05 
were considered as statistically significant. We per-
formed all statistical analyses using SAS version 9.2 
and IBM SPSS, version 21.
Results
Recruitment, treatment allocation and mortality
The 23 LTFU centers had recruited 484 of 718 partici-
pants of the RCT (67%) and provided follow-up data 
on 362 patients (50% of all patients and 75% of 
patients within the LTFU centers). Patient ascertain-
ment within the LTFU centers ranged from 30% to 
100%: We had 17 centers provide LTFU for > 70% 
and four centers provide LTFU for 100% of their ran-
domized patients (Figure 1).
The proportion of treated patients and the type of treat-
ment until Year 10 in the LTFU cohort, based on 
Table 1. Comparison of baseline characteristics of (a) participants and non-participants within the LTFU centers, (b) all patients from 
participating LTFU centers, (c) non-participating centers (non-LTFU centers) and (d) all patients from all centers (EU-SPMS centers). 
 (a) LTFU centers (n = 484) (b) LTFU centers 
(n = 23) (65.7%)
(c) Non-LTFU 
centers (n = 12) 
(34.3%)
(d) EU-SPMS 
centers (n = 35) 
(100%)
participants  
n = 362 (74.8%)
non-participants 
n = 122 (25.2%)
n = 484 (67.4%) n = 234 (32.6%) n = 718 (100%)
Gender female (%) 59.7 52.5 57.9 67.9 (p = 0.0113)b 61.1
Age (y) 41.0 41.5 41.0 41.0 41.0
Disease duration (y since first 
symptoms)
12.4 11.5 12.1 11.4 11.9
Age at onset of MS (y) 27.0 28.0 27.0 28.0 27.0
Time since diagnosis of RRMS (y) 6.7 5.4 (p = 0.0338)b 6.4 6.6 6.4
Patients without relapses in 
previous 2 y (%)
32.0 29.5 31.4 27.4 30.1
Duration of progressive disease (y) 3.0 3.3 3.1 2.9 3.0
EDSS 5.5 5.5 5.5 5.5 (p = 0.0088)b 5.5
EDSS change in previous 2 ya 1.5 1.0 (p = 0.038)b 1.5 1.0 1.5
T2 lesion volume (cm3) 20.6 24.6 21.4 24.5 22.1
aOnly used as predictor variable in a univariate regression model, as only assessed in n = 275 of the participating patients.
bP values < 0.1 are displayed (Wilcoxon-rank-sum test for continuous, Fisher’s exact test for categorical variables, for comparison between (a) participants and 
non-participants within the LTFU centers, (b) between LTFU centers and (c) Non-LTFU centers). Values are medians or proportions.
EDSS: Expanded Disability Status Scale; EU-SPMS: the European SPMS study; LTFU: long-term follow-up; MS: multiple sclerosis; RRMS: relapsing–remit-
ting MS; y: years.
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original randomization to IFNB-1b or placebo, is 
shown in Figure 2. At the end of the OL extension, 
there were 247 (68%) patients on IFNB-1b and 120 
patients (33%) still remained on IFNB-1b at Year 10. 
The number of patients without immunomodulatory 
treatment increased from 82 (23%) at Month 54, to 160 
(44%) at Year 10. The overall median for treatment 
exposure, i.e. the proportion between time on any 
immunomodulatory treatment and the time of observa-
tion, was 65.2%. As expected, this was significantly 
different between the two original treatment groups 
(IFNB-1b: 79.3%; placebo: 52.5%; p < 0.0001).
A total of 24 patients (6.6%) were deceased at a 
median age of 50.2 years (40.6–55.0). Nine patients 
died within the first 5 years of the observation period; 
11 patients had been randomized to IFNB-1b and 13 
to placebo. Their causes of death were considered as 
MS-related in six and seven patients respectively, and 
non-MS-related in two and two patients, respectively, 
and were considered unknown in three and four 
patients whom were randomized to IFNB-1b and pla-
cebo, respectively. Occurrence of deaths was not sig-
nificantly different between the original treatment 
groups (log-rank: p = 0.57).
Sample characteristics of participating and  
non-participating patients
Within the LTFU centers, participating patients had a 
longer time since having the diagnosis of RRMS, 
compared to non-participating patients (6.7 versus 5.4 
years; p = 0.034) and a higher EDSS change in the 2 
years prior to study inclusion (1.5 versus 1.0 points, p 
= 0.038). The latter was only assessed in a subgroup 
of the EU-SPMS cohort (n = 433), and was the only 
variable that was significantly different between the 
LTFU and all non-participating patients (1.5 versus 
1.0 points, p = 0.016).
The comparisons between all patients in the LTFU 
centers (n = 484) and non-LTFU centers (n = 234) 
showed only minor differences at baseline (Table 1): 
There was a slightly higher proportion of patients with 
relapses (58.7% versus 67.1%; p = 0.0334) and a higher 
relapse rate (0.31 versus 0.35; p = 0.0017) in the non-
LTFU centers during the RCT (Table 2). Neutralizing 
antibodies (NAB) against IFNB-1b were detected in 
31% of the LTFU patients with active treatment.
Changes in EDSS from baseline to Year 10
The median baseline EDSS score in the LTFU patients 
was 5.5 (4.0–6.0) and increased to 6.0 (4.5–6.5) at 
Year 3 (observation time: 36.2 months (33.5–38.3)); 
and was 7.0 (6.0–8.0) at Year 10 (observation period: 
124.0 months (120–128)). At Year 10, 31.2% of 
patients were wheelchair-bound (EDSS 7.0–8.0), 
14.1% were bed-ridden (EDSS 8.5–9.5) and 6.6% had 
deceased (Figure 3 and Supplementary Figure S1). 
The median EDSS change was 0.5 (0–1.5) points at 
Year 3 and 2.5 (1.0–3.5) points at Year 10. EDSS 
decreased by 1 point or more in 5.2% of patients; was 
stable (decreased by 0.5, no change or increased by 
0.5 points) in 11.9% of patients; and increased by 
1.0–1.5 points in 17.4% of patients, by 2.0–2.5 points 
in 27.1% of patients, and by ⩾ 3.0 points in 38.4% of 
patients.
Table 2. Randomized controlled trial characteristics of (a) participants and non-participants within LTFU centers, (b) all patients from 
participating LTFU centers, (c) non-participating centers (non-LTFU centers) and (d) all patients from all centers (EU-SPMS centers).
 (a) LTFU centers (n = 23) (b) LTFU centers 
(n = 23)
(c) Non-LTFU 
centers (n = 12)
(d) EU-SPMS 
centers (n = 35)
participants 
n = 362
non-participants 
n = 122
n = 484 n = 234 n = 718
Change in EDSS 0.5 1.0 0.5 1.0 0.5
Confirmed progression (%) 50.8 50.8 50.8 50.4 50.7
Patients with relapses (%) 60.5 53.3 58.7 67.1 (p = 0.0334)a 61.4
Patients becoming wheelchair-bound (%) 22.7 23.0 22.7 25.6 23.7
RR 0.31 0.30 0.31 0.35 (p = 0.0017)a 0.31
Change in T2 lesion volume, median (%) 1.79 −1.63 0.22 1.58 0.96
Patients with > 1 enlarging MRI lesions (%) 58.8 61.5 59.4 60.4 59.8
a P values < 0.1 are displayed (Wilcoxon-rank-sum test for continuous, Fisher’s exact test for categorical variables for comparison (a) between participants and 
non-participants within LTFU centers; and between LTFU (b) centers and the Non-LTFU centers (c). Values are medians or proportions.
EDSS: Expanded Disability Status Scale; EU-SPMS: European SPMS study; LTFU: long-term follow-up; MRI: magnetic resonance imaging; MS: multiple 
sclerosis; RR: relapse rate; RRMS: relapsing–remitting MS; y: years.
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Figure 2. Usage of immunomodulatory treatments by patients participating in the 10-year follow-up, based on the original 
randomization to IFNB-1b or placebo in the RCT. At baseline (Month 0), 186 patients (51.4%) had been randomized 
to IFNB-1b and 176 patients (48.6%) to placebo. At Year 3 (Month 36), we had 143 (40%) patients whom remained on 
IFNB-1b and 214 (60%) patients whom had no treatment. At Month 54, at the end of the open-label extension, there were 
247 patients (68%) on IFNB-1b, 82 patients (23%) on no treatment and 24 patients (7%) on other treatments. At Year 10 
(Month 120), there were 120 patients (33%) on IFNB-1b; 160 patients (44%) had no treatment; and 13 patients (4%) on 
mitoxantrone, 11 patients (3%) on IFNB-1a IM, 10 patients (3%) on methotrexate; while 24 patients (7%) had switched to 
other alternative treatments (proportions include the deceased patients).
IFNB: interferon beta; IM: intramuscular; methotx: methotrexate; mitox: mitoxantrone; PLC: placebo; RCT: randomized controlled trial; 
Tx: treatment.
There were no significant differences in EDSS 
between different treatment allocations at baseline 
(IFNB-1b: 5.5 (4.0–6.0) versus placebo: 5.5 
(4.0–6.0); p = 0.127) and at Year 3 (IFNB-1b: 6.0 
(4.5–6.5) versus Placebo: 6.0 (5.0–6.5); p = 0.161 
(Figure 4)). There appeared to be a trend at Year 10, 
Figure 3. Proportion of EDSS categories over time in LTFU participants. Bars represent the proportion of patients of 
the LTFU sample in different EDSS grades (n = 362) at baseline, at the end of the RCT (Year 3) and at end of the LTFU 
(Year 10).
EDSS: Expanded Disability Status Scale; LTFU: long-term follow-up; RCT: randomized controlled trial.
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in favor of the patients originally randomized to 
IFNB-1b (IFNB-1b: 6.5 (6.0–8.0) versus Placebo: 
7.0 (6.0–8.25); p = 0.086); however, this trend was 
no longer visible when the deceased patients were 
excluded from the analysis (p = 0.13). The EDSS 
change at Year 3 and at Year 10 was not significantly 
different between the treatment groups (IFNB-1b: 
0.5 (0.0–1.5) and 2.5 (1.0–3.5) points; Placebo: 1.0 
(0.0–2.0) and 2.5 (1.0–3.5) points; p = 0.25 and p = 
0.17). At Year 10, the proportion of patients reaching 
EDSS ⩾ 8 or death was not significantly different, 
between the two groups (IFNB-1B: 29% versus 
Placebo: 36.4%; p = 0.29).
Prognostic factors for EDSS at year 10 and 
change in EDSS from end of RCT to year 10
Prognostic factors for the patients’ long-term outcome 
were determined using multivariate linear regression 
models. When considering only baseline variables, 
EDSS at Year 10 and the change in EDSS from the 
end of the RCT to Year 10 were both predicted by 
gender, T2 BOD and EDSS at baseline (Table 3). The 
overall proportion of variability in EDSS at Year 10, 
and the change in EDSS from the end of the RCT to 
Year 10, as explained by these models was 27.0% and 
4.5%, respectively. Baseline EDSS and T2 BOD 
explained the greatest proportion of variability in 
EDSS at Year 10 (24.8%) and the change in EDSS 
from the end of the RCT to Year 10 (2.7%), respec-
tively (Table 3).
When the RCT outcome measures were included 
in the models, both long-term outcomes were 
predicted by the same variables: gender, baseline T2 
BOD, change in T2 BOD during the RCT, baseline 
EDSS, and the change in EDSS during the RCT. It 
is noteworthy that treatment allocation was not 
retained in these models. Altogether, these variables 
explained 51.4% and 11.6% of the total variability 
in EDSS at Year 10 and the change in EDSS from 
the end of the RCT to Year 10, respectively. The 
change in EDSS during the RCT was the main pre-
dictor in both models (EDSS at Year 10: 24.2%; 
change in EDSS to Year 10: 3.2%) (Table 3). 
Notably, EDSS at baseline and the change in EDSS 
during the RCT had a negative regression coeffi-
cient in the models predicting change in EDSS from 
the end of the RCT to Year 10. In all models, having 
the female gender had a small protective effect. The 
EDSS change in the 2 years prior to study inclusion 
(assessment only in a subgroup, n = 275) was not a 
significant predictor of long-term outcomes in our 
univariate analysis.
Finally, we tested the effect of baseline and RCT out-
come measures on patient disability outcomes, only 
within the subgroup of IFNB-1b-treated patients in 
the RCT (Table 3). In contrast to the models run on 
the whole LTFU cohort, the relapse rate during the 
RCT and presence of more than one enlarging lesion 
on MRI during the RCT were weak predictors of 
EDSS at Year 10 and the change in EDSS from the 
end of the RCT to Year 10. The overall proportion of 
variability in EDSS at Year 10 and the change in 
EDSS from the end of the RCT to Year 10, as 
explained by these models, were 51.8% and 11.7%, 
respectively (Table 3).
Figure 4. EDSS at baseline, at the end of the RCT (Year 3) and at end of LTFU (Year 10); by original treatment 
allocation (n = 362). Box plots represent EDSS of the LTFU sample (n = 362) by treatment group (IFNB-1b: n = 186; 
Placebo: n = 176) at baseline, at Year 3 and Year 10.
EDSS: Expanded Disability Status Scale; IFNB: interferon beta; LTFU: long-term follow-up period; RCT: randomized controlled trial.
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The influence of MRI measures on both outcomes 
appeared slightly stronger in the IFNB-1b subgroup 
than in the entire sample, but still explained only 6.0% 
and 5.3% of the variability of EDSS seen at Year 10 and 
the change in EDSS from the end of the RCT to Year 10, 
respectively. Notably, a higher relapse rate was inversely 
associated with both disability outcomes in IFNB-1b-
treated patients, as was baseline EDSS with the EDSS 
change from the end of the RCT to Year 10. The pres-
ence of NAB had no influence on either outcome.
Discussion
This study reports the results of the 10-year multicenter 
long-term follow-up of 362 patients with SPMS whom 
participated in the EU-SPMS treatment trial that tested 
IFNB-1b; it can be considered as a ‘treated history’ 
study.8 We performed an intention-to-treat-analysis to 
explore whether treatment allocation during the RCT 
had a long-term advantage; and we investigated which 
baseline and within-RCT variables were associated 
with disability scores, and the change in disability 
scores, after the 10-year follow-up.
In contrast to the whole sample, the LTFU-cohort 
showed no significant group differences in EDSS 
between the IFNB-1b and Placebo groups of patients, 
at Year 3.8 This may be due to reduced statistical 
power and the influence of unknown variables, since 
the baseline and on-trial characteristics showed no 
relevant differences, in comparison with the non- 
participating patients. A trend in favor of initial 
IFNB-1b treatment was observed at Year 10, but this 
was no longer visible when the 24 deceased patients 
were removed from the analysis.
Long-term observational studies are prone to selec-
tion bias, as patients with more progressive disease 
are more likely to drop from the study.17,18 In addition, 
treatment effects in observational study designs are 
difficult to interpret: Unblinding, EDSS assessments 
without later confirmation and treatment decisions 
taken at the discretion of the physician represent 
potential sources of bias. In our study, selection bias 
may have been limited, because 75% of the patients 
within the participating centers were followed and the 
initial randomization was balanced between centers.
We found that 24 of 362 (6.6%) patients died during 
the 10-year observation period, without differences 
by initial treatment allocation. Given an excess death 
rate of 13 per 1000 person-years in MS,21 more deaths 
Table 3. Final model of EDSS at Year 10 and the changes in EDSS from the end of the RCT to Year 10, in all LFTU patients and those 
randomized to IFNB-1b.
Model Variables Predicting EDSS at Year 10 Predicting a change in EDSS from the 
end of the RCT to Year 10
Coefficient P R2 (%) Coefficient P R2 (%)
Baseline measures for all 
LFTU patients
 
 
 
 
Gender (female) −0.335 0.033 1.0 −0.37 0.0211 1.7
IFNB-1b treatment −0.378 0.015 1.1 – – –
T2 BOD 0.013 0.0008 2.5 0.010 0.0141 1.2
EDSS 0.655 < 0.0001 22.3 −0.17 0.0209 1.5
27.0 4.5
Baseline + on-RCT 
measures for all LFTU 
patients 
 
 
 
 
Gender (female) −0.304 0.018 0.8 −0.366 0.019 1.5
T2 BOD 0.01 0.002 1.5 0.012 0.0017 1.8
T2 BOD change 0.01 < 0.0001 2.2 0.011 0.0004 2.9
EDSS 0.679 < 0.0001 22.7 −0.191 0.0075 2.2
EDSS change 0.569 < 0.0001 24.2 −0.28 < 0.0001 3.2
51.4 11.6
Baseline + on-RCT 
measures (IFNB-1b treated 
patients)
  
> 1 enlarging lesion 0.392 0.042 1.2 0.602 0.0104 2.6
RR −0.387 0.017 1.3 −0.530 0.0072 2.6
T2 BOD change 0.013 0.011 2.3 – – –
T2 BOD 0.014 0.003 2.5 0.016 0.0066 2.7
EDSS 0.618 < 0.0001 20.0 −0.282 0.0067 3.9
EDSS change 0.601 < 0.0001 24.7 – – –
 51.8 11.7
BOD: burden of disease; EDSS: Expanded Disability Status Scale; IFNB: interferon beta; RCT: randomized controlled trial; RR: relapse rate.
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could have been expected; however, as death rates 
have been observed to rise only 20 years after disease 
onset,22 the observation period of this study (about 22 
years after disease onset) may be still too short to 
draw conclusions about mortality outcomes.
We found that the most relevant predictors of EDSS at 
Year 10 were baseline EDSS and EDSS changes dur-
ing the RCT. Similarly, changes in EDSS between the 
end of the RCT and Year 10 were mainly predicted by 
changes in the EDSS during the first 3 years, albeit 
explaining only 3.2% of variability. Interestingly, a 
high EDSS score at baseline and a change in EDSS 
during the RCT were negatively associated with 
EDSS changes at the end of the follow-up period. 
This finding is likely explained by the non-linearity of 
the EDSS scale and the fact that the time needed to 
increase in EDSS category tends to be longer, in 
patients with higher EDSS scores.20 In other words, 
the probability to progress in EDSS is higher at lower 
disability scores, and this is not entirely accounted for 
by considering the changes from EDSS 6.0 to 6.5 and 
from 6.5 to 7.0 as equivalent to a 1.0-point change, as 
we did.
Treatment allocation was a marginal predictor only in 
the model including baseline variables and predicting 
EDSS at Year 10, but not the change in EDSS from 
the end of the RCT to Year 10, corroborating the lack 
of convincing evidence for a more favorable long-
term outcome in patients initially treated with 
IFNB-1b. Treatment exposure during the OL exten-
sion and the LTFU was not included in the model, as 
this variable is probably biased by selection: Stopping 
treatment due to ineffectiveness is more likely in the 
progressing than in the stable patients.
Notably, the contribution of the MRI and pre-RCT 
disease activity measures were only marginal, if not 
absent. Considering the results reported in the RCT, 
the weak contribution of conventional MRI predictors 
is not surprising.19,23 Even in RRMS, where inflam-
mation is more prominent, long-term outcomes are 
only weakly predicted by conventional MRI meas-
ures13; however, the analyses in the current study are 
limited to T2 lesion metrics, as T1 gadolinium-
enhancing and T1 hypointense lesions, as well as 
brain atrophy, were only assessed in small subgroups 
of the EU-SPMS patients.24,25
While the clinical and MRI markers of disease activity 
have been proposed as markers of treatment response 
to IFNB in RRMS,26,27 our results suggested that they 
may be less relevant in the secondary progressive phase 
of the disease. Indeed, prognostic markers in the 
IFNB-1b subgroup were essentially the same as in the 
entire cohort, with only slightly more weight on MRI 
measures; and notably, even an apparent protective 
effect of a higher relapse rate under treatment. However, 
gadolinium-enhancing lesions were only assessed in a 
subgroup of the randomized population and were 
therefore not included in this analysis. In RR MS gado-
linium enhancing lesions have been described to be the 
strongest predictors of long-term treatment response.26
We observed that NAB status had no significant effect 
on the long-term disability outcome. Similarly, the 
NAB status had no significant effect on disease pro-
gression during the randomized controlled phase of 
both the EU-SPMS and the North American SPMS 
trials.10,28
Natural history studies suggest that predictors of the 
time to reach the progressive phase are no longer pre-
dictive, once the progression has started.29–31 During 
progression, a longer time to reach DSS 3 and the 
occurrence of relapses are associated with delayed dis-
ability milestones.2 In our LTFU cohort, relapses dur-
ing the RCT were negatively associated with long-term 
disability, only in the IFNB-1b-treated subgroup, while 
the duration of progressive disease was not predictive 
at all. The persistence of relapses under and despite 
IFNB-1b therapy may indicate the presence of a still 
more inflammatory disease, in which neurodegenera-
tion may be less prominent; however, this is a specula-
tion and these observations remain difficult to explain.
In summary, the progressive phase of MS remains 
largely unpredictable by baseline initial on study con-
ventional MRI measures, and the long-term outcome 
is mostly predicted by the baseline disability and its 
change in the short term. Advanced MRI markers of 
tissue destruction may better predict long-term disa-
bility, as was recently shown for grey matter atrophy,7 
but not for global brain atrophy nor width of third 
ventricle at baseline, in RRMS.13,26 The inclusion of 
other biomarkers derived from cerebrospinal fluid 
and blood samples,32 retinal nerve fibre thickness,33 as 
well as neurophysiological markers,34,35 may improve 
characterization of progressive MS.
In conclusion, the current study showed that the 
SPMS phase remains largely unpredictable by exist-
ing conventional clinical and paraclinical measures.
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